MedTrace Logo

Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer

NCT00898794 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2013-08-07

No results posted yet for this study

Summary

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about the effect of bevacizumab and VEGF on platelet clustering.

PURPOSE: This research study is looking at the effect of bevacizumab and VEGF on platelet clustering in patients with cancer who are receiving bevacizumab.

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific
  • Unspecified Childhood Solid Tumor, Protocol Specific

Interventions

BIOLOGICAL

bevacizumab

OTHER

coagulation study

OTHER

laboratory biomarker analysis

OTHER

platelet aggregation test

Sponsors & Collaborators

  • Kantonsspital Graubuenden

    lead OTHER

Principal Investigators

  • Roger von Moos, MD · Kantonsspital Graubuenden

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2009-05-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00898794 on ClinicalTrials.gov